Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ena-DATASET-UOM-CAP-21-04-2015-13:06:47:615-508 - samples

ABSTRACT: Data from the study of subclonal metastatic expansion in prostate cancer. RNA-seq of twelve samples, tumour and benign tissue, from the four initial patients.

PROVIDER: EGAD00001001345 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Publications

Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.

Hong Matthew K H MK Macintyre Geoff G Wedge David C DC Van Loo Peter P Patel Keval K Lunke Sebastian S Alexandrov Ludmil B LB Sloggett Clare C Cmero Marek M Marass Francesco F Tsui Dana D Mangiola Stefano S Lonie Andrew A Naeem Haroon H Sapre Nikhil N Phal Pramit M PM Kurganovs Natalie N Chin Xiaowen X Kerger Michael M Warren Anne Y AY Neal David D Gnanapragasam Vincent V Rosenfeld Nitzan N Pedersen John S JS Ryan Andrew A Haviv Izhak I Costello Anthony J AJ Corcoran Niall M NM Hovens Christopher M CM

Nature communications 20150401

Tumour heterogeneity in primary prostate cancer is a well-established phenomenon. However, how the subclonal diversity of tumours changes during metastasis and progression to lethality is poorly understood. Here we reveal the precise direction of metastatic spread across four lethal prostate cancer patients using whole-genome and ultra-deep targeted sequencing of longitudinally collected primary and metastatic tumours. We find one case of metastatic spread to the surgical bed causing local recur ...[more]

PMID: 25827447

Similar Datasets

ena-DATASET-UOM-CAP-21-04-2015-13:03:14:947-502 - samples

Project description:Data from the study of subclonal metastatic expansion in prostate cancer. Whole genome shotgun sequencing of fifteen samples, tumour and whole blood, from the four initial patients.

| EGAD00001001343 | EGA

Gene expression profiles of 48 normal and 47 prostate tumor tissue samples

Project description:Large-scale gene expression profiles were investigated in 48 normal and 47 prostate tumor tissue samples using Affymetrix GeneChip Exon 1.0 ST microarrays. Gene expression profiling of human prostate samples using Affymetrix Human Exon 1.0 ST arrays Two disease subtype analyses were performed: - Prostate Tumor vs Benign - TMPRSS2-ERG fusion-positive vs fusion-negative prostate tumors

2011-12-31 | E-GEOD-29079 | biostudies-arrayexpress

21 Breast Cancer Genome Affymetrix SNP6 Array Data

Project description:Cancer evolves dynamically, as clonal expansions supersede or overlap one another, driven by shifting selective pressures, mutational processes and disrupted cancer genes. These processes mark the genome, such that a cancerÕs life history is encrypted in the timing, ploidy, clonality and patterns of somatic mutation. We developed bioinformatic algorithms to decipher this narrative, and applied them to 21 breast cancer genomes. We find that mutational processes evolve across the lifespan of a breast tumor, with cancer-specific signatures of point mutations and chromosomal instability often emerging late but contributing extensive genetic variation. Subclonal diversification is prominent, providing insight into the dynamics of clonal expansion in breast cancer. Most point mutations are found in just a fraction of tumor cells, together with frequent variegation in chromosomal copy number. Every tumor studied here has a dominant subclonal lineage, representing more than 50% of tumor cells. Minimal expansion of these subclones occurs until many hundreds to thousands of mutations have accumulated, implying the existence of long-lived, quiescent lineages of cells that are capable of substantial proliferation upon acquisition of enabling genomic changes. Expansion of the dominant subclone to an appreciable mass may therefore represent the final rate-limiting step in a breast cancer's development, triggering diagnosis.

2012-06-16 | E-MTAB-1087 | biostudies-arrayexpress

ena-DATASET-UOM-CAP-21-04-2015-13:04:36:707-504 - samples

Project description:Data from the study of subclonal metastatic expansion in prostate cancer. Whole genome shotgun sequencing of six samples, tumour and whole blood, from the three additional patients whose somatic variants were examined in depth.

| EGAD00001001344 | EGA

Benign prostate epithelial cell gene expression after four weeks of treatment with daily transdermal DHT or placebo gel

Project description:Significant increases in serum DHT do not increase intraprostatic levels of DHT, PSA, prostate volume, or prostate epithelial cell androgen-regulated gene expression in healthy men. Changes in serum androgen concentrations are not necessarily mimicked within the prostate. Custom Agilent 44K whole human genome expression oligonucleotide microarrays were used to profile benign prostate epithelium from twenty-seven men, twelve of which were treated for four weeks with daily transdermal DHT and 15 which were placebo gel treated controls. All samples were laser-capture microdissected and total RNA isolated and amplified prior to hybridization against a reference reference prostate cell line pool.

2011-01-19 | E-GEOD-20317 | biostudies-arrayexpress

Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression [cell lines]

Project description:Chronic inflammation is known to associate with prostate cancer development, but how epithelium-associated cancer initiating events cross-talk to inflammatory cells during prostate cancer initiation and progression is largely unknown. Using the Pten null murine prostate cancer model, we show an expansion of Gr-1+CD11b+ myeloid-derived suppressor cells (MDSCs) occurring intra-prostatically immediately following epithelium-specific Pten deletion without expansion in hematopoietic tissues. This MDSC expansion is accompanied by sustained immune suppression. Prostatic Gr-1+CD11b+ cells, but not those isolated from the spleen of the same tumor bearing mice, suppress T cell proliferation and express high levels of Arginase 1 and iNOS. Mechanistically, loss of PTEN in the epithelium leads to a significant upregulation of genes within the inflammatory response and cytokine-cytokine receptor interaction pathways, including Csf-1 and IL-1β, two genes known to induce MDSC expansion and immunosuppressive activities. Treating Pten null mice with the selective CSF-1 receptor inhibitor GW2580 decreases MDSC infiltration and relieves the associated immunosuppressive phenotype. Our study indicates that epithelium-associated tumor initiating events trigger the secretion of inflammatory cytokines and promote localized MDSC expansion and immune suppression, thereby promoting tumor progression Custom Agilent 4x44K whole mouse genome expression oligonucleotide microarrays were used to measure transcript levels in murine Pten null prostate cancer cell lines. Benign mouse prostate epithelia as wild type control against cell lines. Each cohort had three biological replicates.

2014-04-03 | E-GEOD-56468 | biostudies-arrayexpress

DENDRO: genetic heterogeneity profiling and subclone detection by single-cell RNA sequencing

Project description:We delineate subclonal expansion in a mouse melanoma models in response to immunotherapy, highlighting the role of neoantigens

2019-11-10 | GSE139248 | GEO

Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression [microdissected tissue]

Project description:Chronic inflammation is known to associate with prostate cancer development, but how epithelium-associated cancer initiating events cross-talk to inflammatory cells during prostate cancer initiation and progression is largely unknown. Using the Pten null murine prostate cancer model, we show an expansion of Gr-1+CD11b+ myeloid-derived suppressor cells (MDSCs) occurring intra-prostatically immediately following epithelium-specific Pten deletion without expansion in hematopoietic tissues. This MDSC expansion is accompanied by sustained immune suppression. Prostatic Gr-1+CD11b+ cells, but not those isolated from the spleen of the same tumor bearing mice, suppress T cell proliferation and express high levels of Arginase 1 and iNOS. Mechanistically, loss of PTEN in the epithelium leads to a significant upregulation of genes within the inflammatory response and cytokine-cytokine receptor interaction pathways, including Csf-1 and IL-1β, two genes known to induce MDSC expansion and immunosuppressive activities. Treating Pten null mice with the selective CSF-1 receptor inhibitor GW2580 decreases MDSC infiltration and relieves the associated immunosuppressive phenotype. Our study indicates that epithelium-associated tumor initiating events trigger the secretion of inflammatory cytokines and promote localized MDSC expansion and immune suppression, thereby promoting tumor progression. Laser-capture microdissection was used to extract epithelial cells from murine benign and Pten null prostate tumors. Their transcript levels were measured by the custom Agilent 4x44K whole mouse genome expression oligonucleotide microarrays. Each cohort had three biological replicates.

2014-04-03 | E-GEOD-56469 | biostudies-arrayexpress

ena-DATASET-IBT-12-06-2013-16:50:34:648-21 - samples

Project description:Small RNA sequencing of 28 untreated prostate cancers, 12 castration resistant prostate cancers, and 3 benign prostatic hyperplasias.

| EGAD00001000611 | EGA

Androgen regulated gene expression in human prostate

Project description:Androgens are a prequisite for the development of human prostate and prostate cancer. Androgen action is mediated via androgen receptor. Androgen ablation therapy is used for the treatment of metastasized prostate cancer. The aim of the study was to identify genes differentially expressed in benign human prostate, prostate cancer and in prostate tissue three days after castration. These genes are potential diagnostic and therapeutic targets for prostate cancer and benign prostatic hyperplasia. We used microarrays to examine the gene expression profiles in benign prostate adjacent to prostate cancer and prostate cancer in radical prostatectomy specimens and in prostate tissue samples taken 3 days after surgical castration performed for treatment of prostate cancer.

2012-06-20 | GSE32982 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data